ITI BioChem is specialized in providing Proteolysis targeting chimeras (PROTACs). 
PROTACs have opened a new chapter for the development of new drugs and novel chemical knockdown tools and brought unprecedented opportunities to the industry and academia, which are heterobifunctional small molecules consisting of a ligand that binds to an E3 ligase, connected by a linker to another ligand that binds to the protein of interest (POI).


Comparison of PROTAC and Other Therapeutics


Degrade the "undruggable" protein target;
Overcoming drug resistance of cancer;
Eliminating both the enzymatic and nonenzymatic functions of the kinase;